Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Share-based Compensation (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Share-based Compensation data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 62.77% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $30.2 million, down 38.94%, while the annual FY2025 figure was $30.2 million, 38.94% down from the prior year.
  • Share-based Compensation reached $3.9 million in Q4 2025 per MRVI's latest filing, down from $9.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.8 million in Q2 2024 and bottomed at $2.2 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $7.2 million, with a median of $6.4 million recorded in 2022.
  • The widest YoY moves for Share-based Compensation: up 348.43% in 2021, down 89.72% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $2.2 million in 2021, then surged by 168.83% to $6.0 million in 2022, then surged by 55.83% to $9.3 million in 2023, then increased by 12.88% to $10.5 million in 2024, then plummeted by 62.77% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $3.9 million in Q4 2025, $9.1 million in Q3 2025, and $6.8 million in Q2 2025.